Mahmoudi Tayebeh, Jalili Ali, Abdolmohammadi Kamal, Fakhari Shohreh, Pahlavan Fatemeh, Shekari Ali, Nikkhoo Bahram, Tayebi Lobat, Rahmani Mohammad Reza
Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Adv Pharm Bull. 2022 Mar;12(2):375-382. doi: 10.34172/apb.2022.036. Epub 2021 Jan 31.
Acute pancreatitis (AP) which is distinguished by local pancreatic necrosis, followingby systemic organ failure is known as an inflammatory disease. Up to now, there are only a fewtreatment options accessible for patients suffering from AP. In this study, we aimed to examinethe anti-inflammatory capacities of human bone marrow-derived mesenchymal stromal cells(hBM-MSCs) in a detailed AP model experiment. AP was induced in C57BL/6 mice by intraperitoneal administration of cerulein (100μg/kg/h × 7 doses) at intervals of 1 hour. Then, 2×10 MSCs were infused in the AP mice bytail vein 6 hours after the last cerulein injection. Mice were sacrificed 12 hours following theinjection of hBM-MSC, and blood samples and pancreas tissues were obtained. We first determined the presence of transplanted hBM-MSC in the pancreas of micewith AP, but not the control mice. Our data indicate that administration of hBM-MSCs to micewith AP lead to (i) decreased serum levels of amylase, lipase and myeloperoxidase activities, (ii)downregulation of proinflammatory cytokine, macrophage inflammatory protein 2 (MIP-2), and(iii) upregulation of the anti-inflammatory cytokine, interleukin 10 (IL-10). Moreover, hBM-MSCadministration results in notably attenuated cerulein-induced histopathological alternationsand edema. we demonstrate that hBM-MSC attenuates AP signs and indicating that hMB-MSCtherapy could be a suitable approach for the treatment of inflammatory disease such as AP.
急性胰腺炎(AP)以局部胰腺坏死为特征,继之出现全身器官衰竭,是一种炎症性疾病。到目前为止,对于患有AP的患者,只有少数几种治疗选择。在本研究中,我们旨在通过详细的AP模型实验来检验人骨髓间充质基质细胞(hBM-MSCs)的抗炎能力。通过腹腔注射蛙皮素(100μg/kg/h×7剂),每隔1小时诱导C57BL/6小鼠发生AP。然后,在最后一次注射蛙皮素6小时后,通过尾静脉向AP小鼠输注2×10的间充质干细胞。在注射hBM-MSC后12小时处死小鼠,获取血液样本和胰腺组织。我们首先在患有AP的小鼠胰腺中检测到移植的hBM-MSC的存在,而在对照小鼠中未检测到。我们的数据表明,给患有AP的小鼠施用hBM-MSCs导致:(i)血清淀粉酶、脂肪酶水平和髓过氧化物酶活性降低;(ii)促炎细胞因子巨噬细胞炎性蛋白2(MIP-2)下调;(iii)抗炎细胞因子白细胞介素10(IL-10)上调。此外,施用hBM-MSCs可显著减轻蛙皮素诱导的组织病理学改变和水肿。我们证明hBM-MSCs减轻了AP的症状,表明hMB-MSC疗法可能是治疗AP等炎症性疾病的合适方法。